{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/lipid-modification-cvd-prevention/goals-outcome-measures/nice-quality-standards/","result":{"pageContext":{"chapter":{"id":"c55b24f4-39a4-5919-8e05-5afc7b1ae5c6","slug":"nice-quality-standards","fullItemName":"NICE quality standards","depth":2,"htmlHeader":"<!-- begin field 371e0175-d10d-4dfd-8866-9b1ffbab327d --><h2>NICE quality standards</h2><!-- end field 371e0175-d10d-4dfd-8866-9b1ffbab327d -->","summary":null,"htmlStringContent":"<!-- begin item 446694e6-5665-4e82-bdbe-80796f51bc93 --><!-- begin field dc8b74a2-9f50-4d25-bb0e-f2d243d0147a --><ul><li>Adults under 85 years with an estimated increased risk of cardiovascular disease (CVD) are offered a full formal risk assessment using the QRISKÂ tool.</li><li>Adults with a 10-year risk of CVD of 10% or more are assessed for secondary causes before any offer of statin therapy.</li><li>Adults with a 10-year risk of CVD of 10% or more receive advice on lifestyle changes before any offer of statin therapy.</li><li>Adults with a 10-year risk of CVD of 10% or more for whom lifestyle changes are ineffective or inappropriate, discuss the risks and benefits of starting statin therapy with their healthcare professional.</li><li>Adults choosing statin therapy for the primary prevention of CVD are offered atorvastatin 20 mg.</li><li>Adults with newly diagnosed CVD are offered atorvastatin 80 mg.</li><li>Adults on a high intensity statin who have side effects are offered a lower dose or an alternative statin.</li><li>Adults on a high intensity statin have a repeat measurement of lipids and liver transaminases after 3 months of treatment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/lipid-modification-cvd-prevention/references/\">NICE, 2015</a>]</p><!-- end field dc8b74a2-9f50-4d25-bb0e-f2d243d0147a --><!-- end item 446694e6-5665-4e82-bdbe-80796f51bc93 -->","topic":{"id":"5303951d-71d9-506d-84ec-cbdd7ff3b93e","topicId":"dc4f1ad8-1fac-4248-9071-a622ca58dd2c","topicName":"Lipid modification - CVD prevention","slug":"lipid-modification-cvd-prevention","lastRevised":"Last revised in October 2020","chapters":[{"id":"7834a360-a716-55db-beef-e74397381f6b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4149ed5c-ad54-5793-8860-4b2f82d94427","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"184e9f02-cec5-5813-a428-f3b70683deda","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0fd087eb-ba58-59e6-b641-2161dd021687","slug":"changes","fullItemName":"Changes"},{"id":"6e535866-055b-5f94-8d43-67cc6c3262a6","slug":"update","fullItemName":"Update"}]},{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3de1ddbe-7a0f-5384-9939-9a56d2251dfc","slug":"goals","fullItemName":"Goals"},{"id":"1a8df6be-f747-5d74-81cf-54d938d5944b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80c40530-2e39-55a1-910d-b5226d83d67a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e9906a94-72bf-5a9e-8e05-bb7b6841fec3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"507f0f33-704f-5b79-813e-0ba2a367617e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c55b24f4-39a4-5919-8e05-5afc7b1ae5c6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f02326a5-5f6d-5026-9c8c-745fd760df23","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f4e4cb23-7f1d-5543-a7a5-9316a25c589b","slug":"lipids-cardiovascular-health","fullItemName":"Lipids and cardiovascular health"}]},{"id":"5123c607-afa6-5c07-a939-547efe27b94c","fullItemName":"Management","slug":"management","subChapters":[{"id":"ec817edb-2375-548c-beb5-8afb1596d294","slug":"lipid-therapy-primary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - primary prevention of CVD"},{"id":"4cd90098-cba6-5b78-994c-9fc173b4fb3f","slug":"lipid-therapy-secondary-prevention-of-cvd","fullItemName":"Scenario: Lipid therapy - secondary prevention of CVD"}]},{"id":"35a2dc51-a5b3-56bd-9a02-c420e08c1d0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3e6af82a-f8f1-5d90-a988-05136fa101f3","slug":"statins","fullItemName":"Statins"}]},{"id":"238b503e-9352-5458-b356-3f6b521ef218","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2dbe7113-fbe3-5fd2-bca1-2846dd9a39c8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fbe34d96-9294-5a30-8de1-1bc1f631ce69","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"df527078-d479-5b6f-aff8-247af2cdd323","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1a8284ce-a2e5-59db-9d07-596f590c3ec3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9fe03c85-09a6-5232-8343-e77d91ad6145","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"d5bce13d-7bb2-5366-8bcc-28f538824ee4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f5e3b9df-860b-5c62-a358-a408038abc28","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6952071a-0b87-50ea-af6b-c7589b86f9bd","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}